¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

Á¦ 1 Â÷ ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ ÅëÇÕÇÐȸ ⸳½ÉÆ÷Áö¿ò : 2021-06-27

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
Á¦ 1 Â÷ ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ ÅëÇÕÇÐȸ ⸳½ÉÆ÷Áö¿ò : 2021-06-27
±³À°ÀÏÀÚ : 2021-06-27
±³À°Àå¼Ò : »ïÁ¤È£ÅÚ ½Å°ü2Ãþ Á¦¶ó´½È¦ ¿Ü  
±³À°ÁÖÁ¦ : Á¦ 1 Â÷ ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ ÅëÇÕÇÐȸ ⸳½ÉÆ÷Áö¿ò
ÁÖÃÖ±â°ü : ´ëÇÑÇǺΰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ  
´ã´çÀÚ : ¿À»óÈ£ ±³¼ö
¿¬¶ôó : 02-2228-2080  
À̸ÞÀÏ : ODDUNG93@yuhs.ac      
±³À°Á¾·ù : ÇǺΰú      
Âü¼®¿¹»óÀοø : 100¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 6 ½Ã°£ 40ºÐ  
¼¼ºÎ¼ö°­·á : 500,000¿ø      
ºñ°í »çÀüµî·Ï: Á¤È¸¿ø(ÇǺΰú Àü¹®ÀÇ) 6¸¸¿ø, ÁØȸ¿ø(ÇǺΰú Àü°øÀÇ) 3¸¸¿ø, ¿¬±¸¿ø 5¸¸¿ø, ºñȸ¿ø 50¸¸¿ø)ÇöÀåµî·Ï: Á¤È¸¿ø(ÇǺΰú Àü¹®ÀÇ) 7¸¸¿ø, ÁØȸ¿ø (ÇǺΰú Àü°øÀÇ) 3¸¸¿ø, ¿¬±¸¿ø 6¸¸¿ø, ºñȸ¿ø 50¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06-27 Á¦¶ó´½ 09:00~09:20 All about photoprotection  À¯È­Á¤(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 09:20~09:40 Proper use of tranexamic acid  Á¤º¸¿µ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 09:40~10:00 Things to consider in treatment of refractory hyperpigmented disorder: Other than laser treatment  ±èÇöÁ¤(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 10:00~10:20 Consensus of opinion in vitiligo treatment  Á¤±âÇå(°æÈñÀÇ´ë) 
È޽Ġ06-27  10:20~10:40 Coffee Break  () 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 10:40~11:00 Melasma pathogenesis: Focus on the dermal milieu  ³ªÁ¤ÀÓ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 11:00~11:20 Treatment of refractory melasma in the real field  ÃÖõÇÊ(ÇϴôÀ³¦ ÇǺΰú) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 11:20~11:40 How to handle mottled hypopigmentation laser toning  ÀÌÇØ¿õ(·çÀÌ ÇǺΰú) 
Åä·Ð 06-27 Á¦¶ó´½ 11:40~12:00 Panel discussion  ±è¹æ¼ø ±èÀ¯Âù(SNU ÇǺΰú ¾ÆÁÖÀÇ´ë) 
½Ä»ç 06-27  12:00~13:30 Á¡½É ½Ä»ç  () 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 13:30~14:00 Motivation of vitiligo research and its progress and future plan  Àֿ̾µ(µ¿±¹ÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 14:00~14:30 Cellular signaling in melanocytes  ¹Ú°æÂù(À»ÁöÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 14:30~14:50 Vitiligo pathogenesis: danger within progressing melanocyte-specific autoimmunity  ÀÌÈñÁ¤(Â÷ÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 14:50~15:10 Determining treatment options according to active and stable vitiligo  À̽ÃÇü(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 15:10~15:30 Updates in surgical treatment for stable vitiligo  ¹èÁ¤¹Î(ÈúÇϿ콺ÇǺΰú) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 15:30~15:50 Upcoming targeted therapy: can JAK inhibitor be a hope for vitiligo patients?  ½ÅÁ¤Çö(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 15:50~16:10 Update of pigmented contact dermatitis: Multicenter study  ÀÌÁ¾Èñ(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 16:10~16:30 Differential diagnosis of hypopigmeted diseases  ÃÖÁ¾¿ø(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06-27 Á¦¶ó´½ 16:30~16:50 Experiment model for the study of pigmentation and vitiligo: 3D skin containing melanocyte  ½ÅÁ¤¿ì(Â÷ÀÇ´ë) 
±³À°½Ã°£ 06-27  16:50~17:10 Senescence and pigmentary change  ¿À»óÈ£(¿¬¼¼ÀÇ´ë) 
Åä·Ð 06-27  17:10~17:30 Wrap up discussion  ÃÖ±¤¼º À̵¿À±(ÀÎÇÏÀÇ´ë ¼º±Õ°üÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" Á¦ 1 Â÷ ´ëÇѹé¹ÝÁõ»ö¼ÒÇÐȸ ÅëÇÕÇÐȸ ⸳½ÉÆ÷Áö¿ò : 2021-06-27""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û 2021³âµµ ´ëÇÑ°¡Á¤ÀÇÇÐȸ Ãá°è¿¬¼ö°­Á : 2021-06-27
´ÙÀ½±Û ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ (¿Â¶óÀÎ) 2021 ´ëÀå³»½Ã°æ ¿¬¼ö°­Á : 2021-06-27
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20895 ¼­¿ï ´ëÇѼҾƽÅÀåÇÐȸ (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-01 0 3 2024-05-28
20894 ´ëÀü Ãæ³²´ëÇб³º´¿ø 2024³â °³¿øÀÇ¿Í ÇÔ²²ÇÏ´Â ³»°ú ¿¬¼ö°­Á : 2024-06-30 0 3 2024-05-28
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 108 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 11 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 35 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 10 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 6 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 4 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 3 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 7 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 1 2024-05-27
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 9 2024-05-27
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 2 2024-05-27
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 8 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷